Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Reporter.
Press releases published on April 30, 2025
Capital Power announces strong first quarter 2025 results
GlobeNewswire
·
April 30, 2025
EDMONTON, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX: CPX) today released financial results for the quarter ended March 31, 2025. Highlights Entered into a definitive agreement to acquire two natural gas-fired power …
authID to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 30, 2025
DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID”), a leading provider of biometric identity verification and authentication solutions, today announced the Company will report financial results for the first quarter ended March 31 …
FuelCell Energy Announces Leadership Transition: Mike Hill Named Chief Commercial Officer to Replace Departing Mark Feasel
GlobeNewswire
·
April 30, 2025
DANBURY, Conn., April 30, 2025 (GLOBE NEWSWIRE) -- FuelCell Energy (NASDAQ:FCEL) today announced a key commercial leadership transition. Industry veteran Mike Hill was appointed as the company’s new Chief Commercial Officer, replacing Mark Feasel. Hill …
Global Uranium Advances Athabasca Basin Exploration with Launch of ZTEM Survey at Astro Project
GlobeNewswire
·
April 30, 2025
CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the "Company" or “Global”) and Cosa Resources Corp. (TSX-V: COSA) (OTCQB: COSAF) (FSE: SSKU) (“Cosa”) are pleased to announce that geophysical …
Intercept Announces Data to be Presented at Digestive Disease Week 2025
GlobeNewswire
·
April 30, 2025
MORRISTOWN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Intercept), part of the Alfasigma Group, today announced 11 submitted abstracts have been accepted for presentation at Digestive Disease Week 2025, including oral …
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
April 30, 2025
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus …
CTS Announces First Quarter 2025 Results
GlobeNewswire
·
April 30, 2025
LISLE, Ill., April 30, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS), a leading global designer and manufacturer of custom engineered solutions that “Sense, Connect and Move,” today announced first quarter 2025 results. “Our global teams continued …
electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025
GlobeNewswire
·
April 30, 2025
ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of …
Infinidat’s InfiniBox® G4 Family Named One of the TOP 5 Cybersecure Sub-10PB NAS Solutions for Enterprises by Storage Analyst Firm DCIG
GlobeNewswire
·
April 30, 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Infinidat, a leading provider of enterprise storage solutions, today announced that leading storage industry analyst firm DCIG has named Infinidat’s InfiniBox® G4 family as one of the world’s TOP 5 …
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
GlobeNewswire
·
April 30, 2025
CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult …
Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
GlobeNewswire
·
April 30, 2025
SYDNEY, April 30, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of this quarter. That milestone will trigger an …
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
GlobeNewswire
·
April 30, 2025
Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications and collaborations Plans to partially spin off RNA …
Best Testosterone Booster Supplement for Males Over 40: Why TestoPrime Leads for Muscle, Energy & Libido
GlobeNewswire
·
April 30, 2025
New York City, April 30, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Testosterone Support Matters After 40 As men age, maintaining strength, stamina, and masculinity becomes increasingly difficult — and one of the biggest reasons is a steady decline in …
Kymeta Supercharges Leadership with Top Defense, Space and Tech Experts to Tackle Global Security Challenges
GlobeNewswire
·
April 30, 2025
Kymeta announces the addition of four prominent leaders to its Board of Directors and Board of Advisors The appointments come as global demand for secure, sovereign communication systems intensifies, particularly in Europe, Indo-Pacific and other allied …
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire
·
April 30, 2025
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
GlobeNewswire
·
April 30, 2025
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at the American Academy of Neurology …
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
GlobeNewswire
·
April 30, 2025
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits Positive …
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewswire
·
April 30, 2025
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ …
NanoXplore to Host a Webcast to Discuss Third Quarter Results on May 14th, 2025
GlobeNewswire
·
April 30, 2025
MONTREAL, April 30, 2025 (GLOBE NEWSWIRE) -- NanoXplore Inc. (“NanoXplore”) (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its third quarter ended March 31st, 2025, on Wednesday, May 14, 2025, at 10:00 a.m. Eastern Time. …
NanoXplore organise une webdiffusion pour discuter des résultats du troisième trimestre le 14 mai 2025
GlobeNewswire
·
April 30, 2025
MONTRÉAL, 30 avr. 2025 (GLOBE NEWSWIRE) -- NanoXplore Inc. (" NanoXplore " ou la " Société ") (TSX : GRA et OTCQX : NNXPF) a le plaisir d'organiser une webdiffusion pour discuter des résultats de son troisième trimestre clos le 31 mars 2025, le mercredi 14 …